Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22307476 | 0.80 | L3MBTL1 (0.48) | ALPLALPIALPGHPGDTSHR | |
| SCHEMBL22307492 | 0.79 | ALPL (0.59) | ALPLALPIALPGP2RX7LOXL2 | |
| SCHEMBL22307900 | 0.79 | ALPL (0.59) | ALPLALPIALPGP2RX7LOXL2 | |
| SCHEMBL22307899 | 0.79 | ALPL (0.59) | ALPLALPIALPGP2RX7LOXL2 | |
| SCHEMBL22307411 | 0.78 | NPC1 (0.54) | ALPLALPIALPGP2RX7CA2 | |
| SCHEMBL22308374 | 0.78 | LOXL2 (0.47) | ALPLALPIALPGHPGDTSHR | |
| SCHEMBL22307415 | 0.78 | ALPL (0.49) | ALPLALPIALPGP2RX7CA2 | |
| SCHEMBL22307430 | 0.76 | P2RX7 (0.48) | ALPLALPIALPGP2RX7LOXL2 | |
| SCHEMBL22307450 | 0.76 | ALPL (0.53) | ALPLALPIALPGP2RX7CA2 | |
| SCHEMBL13683247 | 0.76 | TSHR (0.65) | HPGDTSHRP2RX7CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247762-A1 | K-RAS MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247762-A1 | K-RAS MODULATORS | KRAS, HRAS, NRAS | ALPL 4807/4885ALPI 4014/4885ALPG 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.